Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...

Despite effective HIV medication, the immune system of people with HIV remains disrupted in the long term.

Gilead’s investigational drug combo bic/len could help lower the pill burden in patients with virologically suppressed HIV ...

Merck said on Wednesday that its experimental oral HIV treatment met the main goal of a late-stage trial. The company said ...

Lenacapavir is an injectable medicine that only needs to be taken twice a year, making it easier to use than daily HIV pills.

Funding for HIV care and prevention are key for continued progress, but recent cuts to federal funding for health agencies, ...

The United States, whose deep cuts to foreign aid this year under President Trump have severely impacted Africa’s health ...

Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...

Merck reports positive results from phase 3 trial of once-daily, oral, two-drug, single-tablet regimen of Doravirine/Islatravir in treatment-naïve adults with HIV-1 infection ...

Medicaid expansion under the Affordable Care Act (ACA) significantly increased the number of people at risk of HIV diagnosis ...

Despite effective HIV medication, the immune system of people with HIV remains disrupted in the long term. Researchers at ...

Organizations that provide services like HIV education and living recommendations are being forced to cut programming after ...